Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Table 4.5.7 continued
Author
Year
Reference
Country
Study design
Population
characteristics
Intervention/
Method (I)
Control Results Withdrawal
Drop outs
Study quality
and relevance
Comments
Wymenga
1991
[25]
The Netherlands
Additional
results from
Wymenga
1992 [54]
THR from above trial,
TKR added
Mean follow-up
13 months, no strict
follow-up plan
I: As above As above Joint sepsis
I: 14/1 502 (0.9%)
C: 12/1 511 (0.8%)
ns
Re-op
NA
High
Follow-up random.
Multiple endpoints
Death
NA
All wound infections
I: 29/1 502 (1.7%)
C: 40/1 511 (2.6%)
ns
Wymenga
1992
[54]
The Netherlands
RCT, open
multicenter.
Includes power
calculation
THR
Excl: allergy, recent ab
(48 h), infected joint,
malign, ab-cement
Mean follow-up
13 months, no strict
follow-up plan
I: Cefuroxime 1.5 g
30 min pre-op
(n=1 327)
C: Cefuroxime
1.5 g 30 min
pre-op + 0.75 g
8 and 16 h later
(n=1 324)
Joint sepsis
I: 11/1 327 (0.83%)
C: 6/1 324 (0.45%)
ns
Re-op
I: 33/1 327 (2.5%)
C: 31/1 324 (2.3%)
ns
145 withdrawn,
15 lost to
follow-up.
No infections
in the withdrawn
cohort
High
Follow-up random.
Multiple endpoints
Death
I: 43/1 327 (3.2%)
C: 30/1 324 (2.3%)
ns
All wound infection
I: 25/1 327
C: 31/1 327
ns
Ab = Antibiotics; C = Control group; I = Intervention group; ITT = Intention-to-treat;
NA = Not applicable; ns = Non significant; pts = Patients; RCT = Randomised controlled
trial; THA = Total hip arthroplasty register; THR = total hip replacement; TKA = Total
knee arthroplasty; TKR = Total knee replacement
308 antibiotikaprofylax vid kirurgiska ingrepp KAPITEL 4 • den systematiska litteraturöversikten
309